Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ABF656
Albinterferon alfa 2b · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| alb-interferon arm 1 | EXPERIMENTAL | - |
| alb-interferon arm 2 | EXPERIMENTAL | - |
| alb-interferon arm 3 | EXPERIMENTAL | - |
| alb-interferon arm 4 | EXPERIMENTAL | - |
| peg-interferon | ACTIVE_COMPARATOR | - |
| 1 | EXPERIMENTAL | Open-label treatment with albinterferon alfa 2b escalating single dose |
| Name | Type | Description |
|---|---|---|
| alb-interferon alfa 2b | DRUG | 900 mcg every 4 weeks |
| peg-interferon | DRUG | Peg-interferon alfa 2a: 180 mcg 1x per wk. |
| Albinterferon alfa 2b | BIOLOGICAL | recombinant human albumin-interferon alfa fusion protein, 600-1800mcg single dose by S.C. on Day 0 |
Inclusion Criteria: * Age of 18 years or older * Clinical diagnosis of chronic hepatitis C * Infection with HCV genotype 2 or 3 * No previous IFNα-based therapy Exclusion Criteria: * Women of child-bearing potential if not using double barrier method of contraception, pregnant or nursing * Fertil...
Albinterferon alfa 2b is an investigational therapy being studied for the treatment of chronic hepatitis C, a viral infection of the liver. It is designed to be given less frequently than standard interferon-based regimens. It has been tested in patients with chronic hepatitis C, including genotype 2 and 3 infections.
Albinterferon alfa 2b is an agonist that targets the interferon alpha receptors IFNAR1 and IFNAR2. By binding to and activating these receptors, it mimics the body's natural interferon alpha signaling, which triggers antiviral responses in cells. This mechanism is intended to help the immune system fight hepatitis C virus infection.
Albinterferon alfa 2b is being developed by Novartis AG, which trades under the ticker NVS. Novartis is the company responsible for the clinical development of this investigational hepatitis C therapy.
Albinterferon alfa 2b is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 2 program has been completed, and no active trials are currently listed for this candidate.
Albinterferon alfa 2b has been studied in two completed clinical trials. NCT00759200 was a Phase 2 trial evaluating safety and efficacy when administered every 4 weeks in genotype 2/3 hepatitis C patients, enrolling 525 participants across multiple countries. NCT00724776 was a Phase 1 single-dose trial in 30 Japanese chronic hepatitis C patients.
Yes, albinterferon alfa 2b and alb-interferon alfa 2b refer to the same investigational drug. The hyphenated spelling is an alternative name for the same compound being developed by Novartis for chronic hepatitis C.